Discovering the world’s
next generation of treatments

We are a clinical-stage biopharmaceutical company focused on the discovery & development of novel antibiotics, antifungals, and treatments for certain cancers and dermatological conditions.

Antibiotic Platform

Biocidium has developed a novel broad-spectrum antibiotic. Our antibiotic has proven 99.99%+ efficacy against 90%+ of bacteria listed by the CDC, FDA and ESKAPE Program as drug-resistant or multi-drug resistant bacteria including MRSA, VRE, CRE, E. coli, and Klebsiella pneumoniae, among others.

Antifungal Platform

Our antifungals have shown excellent efficacy against 100% of fungal infections listed by both the CDC and FDA as drug-resistant and multi-drug resistant fungi including Candida auris, Fluconazole-resistant Candida albicans, Cryptococcus neoformans, and others.

Oncology Platform

Biocidium continues to build out its oncology platform with a current focus on developing anti-cancer drugs for Melanoma, Basal cell carcinoma (BCC), Squamous cell carcinomas (SCC), Cutaneous lymphoma, and Adenocarcinoma.


Biocidium has made headway into the treatment and cure for a range of skin conditions, from simple infections to tackling Carcinoma. We are developing products that may someday offer simple topical spot application for diseases that previously required invasive oral medication.

Biocidium Solutions

Biocidium has a significant IP portfolio, built over decades with a focus on bio-pharma solutions. Biocidium’s proprietary high efficacy/low toxicity antibiotics represent innovative advances in a bio-based comprehensive solution to these harmful diseases. Biocidium is one of the only companies that has developed both individual and combined gram-positive and gram-negative antibiotics. Biocidium’s most advanced development projects are:

BCM-0184 – A novel antibiotic which in pre-clinical trials has proven to kill MRSA(methicillin resistant Staphylococcus aureus)

BCM-0241 – A novel antibiotic which in pre-clinical trials has proven to kill VRE (vancomycin resistant Enterococcus)

BCM-0316 – A novel antibiotic which in pre-clinical trials has proven to kill CRE(carbapenem-resistant Enterobacteriaceae)

BCM-0112 – A topical cream for the treatment of some melanocytic nevi, and melanoma-in-situ (lentigo maligna)

Biocidium fully understands the responsibility it has to develop, register and treat live threatening bacteria and conditions. Our work allows us the opportunity to help many patients by developing solutions that are both stand-alone, and compounds based on our extensive expertise.

At Biocidium, we are driven by the extraordinary promise of our research. We see the potential of our work for helping people suffering with conditions ranging from common but debilitating dermatological issues, all the way to the life-altering prognosis of cancer. Our ongoing successful results inspire our team to keep making progress, with the prospect of bringing treatments to market visible on the horizon.

A Growing Bacterial Resistance

As antibiotic resistance grows, the antibiotics used to treat infections do not work as well or at all. The loss of effective antibiotic treatments will not only cripple the ability to fight routine infectious diseases but will also undermine treatment of infectious complications in patients with other diseases. Many of the advances in medical treatment—joint replacements, organ transplants, cancer therapy, and treatment of chronic diseases such as diabetes, asthma, rheumatoid arthritis—are dependent on the ability to fight infections with antibiotics. If that ability is lost, the ability to safely offer people many life-saving and life-improving modern medical advantages will be lost with it.

The next 20 years will see a significant growth our world’s elderly population. This segment requires the greatest number of operations, typically lives in shared accommodation, have weaker immune systems and are generally more susceptible to hospital acquired infections (HAI’s).

Today, The Infectious Disease Society of America estimates that the annual cost to the U.S. healthcare system of infections caused by antibiotic-resistant bacteria is $21 billion to $34 billion, including 8 million additional hospital days. Seventy years after the beginning of the “antibiotic era,” there is an acute and growing public health need for new treatments to address infections caused by MDR bacteria.